CD274 and gastric cancer: The KEYNOTE-062 phase 3 study evaluated pembrolizumab with or without chemotherapy versus chemotherapy alone in the first-line setting for GC, demonstrating noninferiority of pembrolizumab monotherapy relative to chemotherapy in patients with a programmed cell death-ligand 1 (PD-L1) combined positive score (CPS) of ≥1 [11].